The "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...
Analysts expect a loss of 41 cents per share on revenue of $168.3 million, representing year-over-year revenue growth of 4.4%. The expected loss would widen from the 33-cent deficit reported in the ...
On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine ...
Wednesday, Novocure Ltd (NASDAQ:NVCR) released data from the Phase 3 METIS clinical trial of Tumor Treating Fields (TTFields) therapy. The study met its primary endpoint, demonstrating a statistically ...
Analysts' ratings for NovoCure (NASDAQ:NVCR) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following table provides a quick overview of their recent ratings, ...
Visit a quote page and your recently viewed tickers will be displayed here. Jeryl Lynn Hilleman currently works at Omada Health, Inc., as Chairman, SI-BONE, Inc., as Independent Director from 2019, ...
Investors in NovoCure Ltd (Symbol: NVCR) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVCR ...
In trading on Friday, shares of NovoCure Ltd (Symbol: NVCR) crossed above their 200 day moving average of $16.55, changing hands as high as $16.60 per share. NovoCure Ltd shares are currently trading ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in ...
The company’s U.S. subsidiary, Novocure Inc., received a letter from CMS on Monday rescinding a prior revocation of billing privileges. CMS stated the company’s Medicare billing privileges are ...
ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $24.5 million in its fourth quarter. The St. Helier, Jersey-based company said it had a loss of ...
* NOVOCURE LTD - CONTINUING TO TREAT CURRENT CLINICAL TRIAL PATIENTS & ENROLL NEW PATIENTS AT EXISTING CLINICAL TRIAL SITES IN 6 ONGOING CLINICAL TRIALS * NOVOCURE LTD - COVID-19-RELATED EFFECTS ARE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results